Varices and variceal bleed resident survival guide: Difference between revisions
Rim Halaby (talk | contribs) m Rim Halaby moved page Approach to variceal bleed to Variceal bleed resident survival guide |
No edit summary |
||
Line 20: | Line 20: | ||
{{familytree/end}} | {{familytree/end}} | ||
Algorithm according to American Association for the Study of Liver Diseases (AASLD) practice guidelines. <ref name="pmid17879356">{{cite journal| author=Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Practice Parameters Committee of the American College of Gastroenterology| title=Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. | journal=Hepatology | year= 2007 | volume= 46 | issue= 3 | pages= 922-38 | pmid=17879356 | doi=10.1002/hep.21907| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17879356}}</ref> | Algorithm according to American Association for the Study of Liver Diseases (AASLD) practice guidelines. <ref name="pmid17879356">{{cite journal| author=Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Practice Parameters Committee of the American College of Gastroenterology| title=Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. | journal=Hepatology | year= 2007 | volume= 46 | issue= 3 | pages= 922-38 | pmid=17879356 | doi=10.1002/hep.21907| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17879356}}</ref> | ||
==Management of actively bleeding varices== | |||
{{familytree/start}} | |||
{{familytree | | | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | |A01=<div style="float: left; text-align: left; line-height: 150% ">'''Suspected acute variceal hemorrhage''' | |||
---- | |||
❑ Patient with known cirrhosis and/ <br> ❑ Coffee ground emesis <br> | |||
</div> }} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | |B01=<div style="float: left; text-align: left; line-height: 150% "> | |||
'''General measures:''' | |||
------ | |||
❑Admit the patient to ICU<br> | |||
❑ Assess airway<br> | |||
❑ Obtain peripheral venous access<br> | |||
❑ Intravascular volume resuscitation<br> | |||
❑ Blood transfusion (to maintain a hemoglobin of 8mg/dl)</div> }} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | | |C01=<div style="float: left; text-align: left; line-height: 150% ">'''Prophylactic antibiotics''' | |||
------ | |||
❑ Oral [[norfloxacin]] (400mg BID)OR <br> ❑ IV [[ciprofloxacin]] <br> | |||
❑IV ceftriaxone (1g/day) in advanced cirrhosis </div>}} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | D01 | | | | | | | | | | | | | | | | | | | |D01=<div style="float: left; text-align: left; line-height: 150% ">'''Pharmacologic therapy:''' | |||
---- | |||
❑ Vasopressin (IV infusion 0.2 to 0.4 units/min up to 0.8 units/min)+ Nitroglycerine (IV 40 μg/min can be increased up to 400 μg/min) OR<br> | |||
❑ Terlipressin (IV 2 mg/4 hours titrated down to 1 mg/4 hours), not available in US, OR<br> | |||
❑ Somatostatin (250 μg IV bolus followed by 250 μg/hr continuous infusion) OR<br> | |||
❑ Octreotide (somatostatin analogue), IV bolus of 50μg followed by continuous infusion 50μg/hour </div>}} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | E01 | | | | | | | | | | | | | | | | | | | |E01=<div style="float: left; text-align: left; line-height: 150% ">'''Endoscopic therapy''' | |||
---- | |||
❑ Early EGD recommended for diagnosis and treatment (with in 12 hours of admission)<br> | |||
❑ Endoscopic variceal ligation (preferred)<br> | |||
❑ Sclerotherapy (if EVL is not feasible) | |||
</div>}} | |||
{{familytree/end}} |
Revision as of 23:12, 29 December 2013
Approach to varices in a cirrhotic patient
Patient diagnosed with cirrhosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No active bleeding | Active bleeding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Screening EGD | See below | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No varices | Esophageal varices | Gastric varices | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensated cirrhosis | De-compensated cirrhosis | Small(<5mm) | Medium/Large(>5mm) | Cyanoacrylate or EVL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repeat EGD in 3 years | Repeat EGD annually | High risk of hemorrhage† | Not at high risk of hemorrhage‡ | High risk of hemorrhage† | Not at high risk of hemorrhage‡ | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Non selective beta blockers | Non selective beta blockers can be used (long tern benefits not established) | Non selective beta blockers (propanolol,nadolol) or EVL | Non selective beta blockers preferred (propanolol, nadolol), EVL in case of contraindication or intolerance to beta blockers | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Algorithm according to American Association for the Study of Liver Diseases (AASLD) practice guidelines. [1]
Management of actively bleeding varices
Suspected acute variceal hemorrhage
❑ Patient with known cirrhosis and/ | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
General measures: ❑Admit the patient to ICU | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prophylactic antibiotics
❑ Oral norfloxacin (400mg BID)OR | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacologic therapy:
❑ Vasopressin (IV infusion 0.2 to 0.4 units/min up to 0.8 units/min)+ Nitroglycerine (IV 40 μg/min can be increased up to 400 μg/min) OR | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Endoscopic therapy
❑ Early EGD recommended for diagnosis and treatment (with in 12 hours of admission) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- ↑ Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases. Practice Parameters Committee of the American College of Gastroenterology (2007). "Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis". Hepatology. 46 (3): 922–38. doi:10.1002/hep.21907. PMID 17879356.